S652
Clinical – Head & neck
ESTRO 2026
Conclusion: Combined-modality treatment with surgery followed by adjuvant radiotherapy achieved excellent local control and long-term survival in patients with non- metastatic ONB. Modern RT techniques such as VMAT ensured effective target coverage with acceptable toxicity. A multidisciplinary approach remains essential for optimizing outcomes in this rare malignancy. Keywords: Olfactory Neuroblastoma, Adjuvant RT,Head and neck Digital Poster Highlight 4176 Prognostic Impact of Pretreatment EBV-DNA Copy Number per Unit Tumor Volume in Nasopharyngeal Carcinoma Patients – A Retrospective Single-Center Study Mehmet Varol 1 , Recep Faruk Özalp 2 , Ece Özkaya 1 , Halit Can Koç 1 , Mehmet Ça ğ rı Duymaz 1 , Hasan O ğ uz Çetinayak 1 1 Department of Radiation Oncology, Dokuz Eylul University, Izmir, Turkey. 2 Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkey
Purpose/Objective: Olfactory Neuroblastoma (NB) is a rare sinonasal malignancy with a high-risk of local recurrence. Although combined-modality therapy is widely adopted, data on long-term outcomes and optimal treatment sequencing are limited. The purpose of this study is to analyze the clinical behavior, recurrence pattern, survival outcomes and treatment-related toxicity of this neoplasm. Material/Methods: A retrospective review was conducted on patients with ONB treated between 1999 and 2025 at a tertiary-care university hospital. Adjuvant treatments were administered according to institutional protocols, based on pathological risk factors and multidisciplinary tumor board recommendations. Outcomes assessed included local control (LC), progression-free survival (PFS), overall survival (OS), treatment-related toxicity, and failure patterns. Results: Eighty-seven patients (51 females, 36 males; median age 55 years, range 14–85) were included. Surgical approaches comprised exclusive endonasal resection in 17 cases (19.5%), endoscopic resection with transnasal craniectomy in 64 (73.6%), and cranio- endoscopic resection in 6 (6.9%). Final pathological staging showed 10 patients (11.5%) with Kadish-INSICA A disease, 46 (52.9%) with B, 30 (34.5%) with C, and 1 (1.1%) with DN. Negative margins (R0) were achieved in 73 patients (83.9%), while 12 (13.8%) and 2 (2.3%) had microscopic (R1) and macroscopic (R2) residual disease, respectively, mostly in Kadish C tumors.Adjuvant radiotherapy (RT) was delivered to 75 patients, including 4 who received concurrent chemoradiotherapy. Photon-based RT was administered in 72 cases (3D-CRT in 12, VMAT in 60), and 3 patients underwent particle therapy at external centers. The median total dose was 60 Gy (range 50– 70 Gy) to the primary tumor bed and 54 Gy to elective nodal levels. Most patients developed grade 1–2 mucositis or erythema, with no ≥ grade 3 late toxicity (CTCAE v5.0).After a median follow-up of 75 months (range 5–206 months), the 5- and 10-year LC rates were 89.4% and 75.6%, respectively; PFS rates were 89.4% and 68.3%, and OS rates were 96.2% and 88.9%. Fourteen patients (16.1%) experienced recurrence: 50% involved both local and nodal sites, 35.7% were nodal-only, and 14.3% were local-only. Notably, 28.6% of recurrent patients had not received adjuvant RT.
Digital Poster 4206
Definitive Chemoradiotherapy Outcomes in Cervical Esophageal Carcinoma: A Single Institution Experience Maria Tariq, Waqas Ahmed Khan, Fabiha Shakeel, Ahmed Nadeem Abbasi, Asim Hafiz, Bilal Mazhar Qureshi, Nasir Ali Oncology, Aga Khan University, Karachi, Pakistan Purpose/Objective: Cervical esophageal carcinoma(CEC) is rare, accounting for 2–10% of all esophageal cancers.Due to its proximity to critical structures,surgery carries significant morbidity and mortality. Definitive chemoradiotherapy(CRT) remains the preferred treatment. This study reviews treatment outcomes, response rates, and recurrence patterns in patients with CEC treated with radical-intent CRT at a tertiary
Made with FlippingBook - Share PDF online